Below is information on how Dupixent works to treat asthma. How a medication works is also called its mechanism of action. Note: Dupixent should not be used to treat an asthma attack. The ...

The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold ... enthusiasm about the progress of this mechanism of action. Positive outcomes from clinical trials ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The use of Dupixent in AD has set a high benchmark ... pharmaceutical companies are investigating agents with different mechanisms of action to provide alternatives to the current standard of ...